Floatz logo

Fragmin

Bleeding

Helsinki University Central HospitalPhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Bleeding cohort.

Asset / SponsorPhaseRating
Rivaroxaban
Icahn School of Medicine at Mount Sinai
Phase 4BBB
Dabigatran
St. Antonius Hospital
Phase 4BBB
Acetylsalicylic Acid
China National Center for Cardiovascular Diseases
Phase 4BBB
Plavix
Icahn School of Medicine at Mount Sinai
Phase 4BBB
WARFARIN
China National Center for Cardiovascular Diseases
Phase 4BBB

View all 20 →

Same molecule, other indications

Fragmin is also rated in:

venous thromboembolismDormant
BBB
Indicative ·
73 / 100
View asset →
Veno-occlusive DiseaseDormant
BB
Indicative ·
65 / 100
View asset →
plasma cell myelomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →